Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer
- 1 January 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (1) , 136???139
- https://doi.org/10.1097/00005392-200601000-00035
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Risk of Fracture after Androgen Deprivation for Prostate CancerNew England Journal of Medicine, 2005
- Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapyCancer, 2004
- Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancerBJU International, 2000
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- BONE MINERAL DENSITY IN MEN TREATED WITH SYNTHETIC GONADOTROPIN-RELEASING HORMONE AGONISTS FOR PROSTATIC CARCINOMAJournal of Urology, 1999
- The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinomaCancer, 1998
- Osteoporosis After Orchiectomy for Prostate CancerJournal of Urology, 1997
- Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogensCalcified Tissue International, 1995
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993